Swiss physicians surveyed had treated 1,048 patients under legal psychedelic-assisted therapy exemptions, using psilocybin in 85.4% of practices, MDMA in 70.7%, and LSD in 65.9%. Patients received an average of 5.1 substance sessions, usually spaced 3 months apart, with psilocybin most often preferred for depression, somatic issues, and substance use disorder. This is one of the clearest looks at how psychedelic therapy actually works outside clinical trials, including preparation, integration, music, co-sitters, consent, adverse effects, and real access barriers.